Compounds > adenosine diphosphate ribose

adenosine diphosphate ribose and Epithelial Ovarian Cancer

adenosine diphosphate ribose has been researched along with Epithelial Ovarian Cancer in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	8 (100.00)	2.80

Authors

Authors	Studies
Au-Yeung, G; Freimund, A; Friedlander, M; Krasovitsky, M; Lee, YC; Mileshkin, L; Norris, C; Sivakumaran, T; So, J; Webber, K	1
Barberis, M; Betella, I; Bonaldo, G; Colombo, N; Fumagalli, C; Guerini-Rocco, E; Ranghiero, A; Rappa, A; Vacirca, D	1
Belogurov, AA; Chen, G; Chen, Z; He, Q; Li, X; Lin, S; Liu, Y; Tian, J; Yang, M; Zhang, F	1
Aprile, G; Candela, MV; Ferrario, L; Giuliani, J; Mantoan, B	1
Coleman, RL; Colombo, N; Dean, A; Denys, H; Esteves, B; Harter, P; Konner, JA; Lorusso, D; Marin, MR; Matulonis, UA; Method, M; Murphy, CG; Noble, E; Oaknin, A; Pignata, S; Van Gorp, T; Wang, J	1
Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E	1
Bachvarov, D; Bachvarova, M; Gregoire, J; Masson, JY; Navarro, JM; Perez, RB; Plante, M; Renaud, MC; Sebastianelli, A; Sheta, R	1
Bartoletti, M; Cecere, SC; Musacchio, L; Pignata, S; Puglisi, F; Sorio, R	1

Trials

1 trial(s) available for adenosine diphosphate ribose and Epithelial Ovarian Cancer

Article	Year
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 05-01, Volume: 41, Issue:13 Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Folate Receptor 1; Humans; Immunoconjugates; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors	2023

Article

Year

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 05-01, Volume: 41, Issue:13

Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Folate Receptor 1; Humans; Immunoconjugates; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors

2023

Other Studies

7 other study(ies) available for adenosine diphosphate ribose and Epithelial Ovarian Cancer

Article	Year
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2022, 07-04, Volume: 32, Issue:7 Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Australia; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Retrospective Studies	2022
In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica, 2022, Volume: 114, Issue:4 Topics: Adenosine Diphosphate Ribose; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Feasibility Studies; Female; Formaldehyde; Genomic Instability; Humans; Ovarian Neoplasms; Recombinational DNA Repair; Reproducibility of Results	2022
SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair. Disease markers, 2022, Volume: 2022 Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; DNA; Female; Humans; Irinotecan; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair	2022
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:2 Topics: Adenosine Diphosphate Ribose; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2023
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer research, 2023, Volume: 43, Issue:3 Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia	2023
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. Journal of translational medicine, 2020, 11-19, Volume: 18, Issue:1 Topics: Adenosine Diphosphate Ribose; Biomarkers; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors	2020
Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices. ESMO open, 2021, Volume: 6, Issue:3 Topics: Adenosine Diphosphate Ribose; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors	2021